Bioceltix

Bioceltix EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioceltix (BCX.WA) as of Oct 21, 2026 is -17.32 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -18.26 M PLN — a change of -5.15% (higher).

EBITDA

-17.32 MPLN

YoY

-5.15%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioceltix is 2025 -17.32 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioceltix was 2024 -18.26 M PLN. It decreases by -5.15% higher compared to the previous year.

The Bioceltix EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.92 M PLN
Jan 1, 2019
-3.73 M PLN
Jan 1, 2020
-3.77 M PLN
Jan 1, 2021
-5.84 M PLN
Jan 1, 2022
-9.23 M PLN
Jan 1, 2023
-15.38 M PLN
Jan 1, 2024
-18.26 M PLN
Jan 1, 2025
-17.32 M PLN
The Bioceltix EBITDA history
YEAREBITDAYoY
-17.32 MPLN-5.15%
-18.26 MPLN+18.66%
-15.38 MPLN+66.73%
-9.23 MPLN+58.10%
-5.84 MPLN+54.98%
-3.77 MPLN+1.02%
-3.73 MPLN+94.16%
-1.92 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bioceltix Stock analysis

What does Bioceltix do? Bioceltix SA focuses on research and development within the field of veterinary medicine, specifically targeting the treatment of companion animals. The company develops candidates for veterinary medicinal products by utilizing the immunomodulatory properties of mesenchymal stem cells as the active substance. This scientific approach allows the firm to conduct research and development works that facilitate clinical trials and the full registration of these medicinal products with the European Medicines Agency, adhering to standards similar to those for human medicines. Bioceltix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioceltix stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioceltix is -17.32 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioceltix changed from -18.26 M PLN to -17.32 M PLN, representing a -5.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Bioceltix since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Bioceltix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Bioceltix

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Bioceltix